Cingulate Inc. (CINGW) Stock Price & Analysis
Cingulate Inc. (CINGW) rose 0.00% to USD 0.02 as of June 10, 2026 at 15:30 UTC, according to Nexqual real-time market data.
CINGW last closed at USD 0.02; the session ranged USD 0.02–0.03 on volume of 5,830 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.03 (NCM). Source: Nexqual, June 10, 2026 at 15:30 UTC.
Key Statistics (as of June 10, 2026 at 15:30 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.04 |
| Day Range | USD 0.02 – 0.03 |
| 52-Week Range | USD 0.02 – 0.03 |
| Volume | 5,830 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CINGW)
Nexqual's technical model rates CINGW "BUY" based on 5 bullish and 2 bearish signals across 66 daily candles, as of June 10, 2026 at 15:30 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.06) |
| MACD | 0 (positive) |
Analyst Ratings (CINGW)
Wall Street analysts rate CINGW "None", per Nexqual as of June 10, 2026 at 15:30 UTC.
| Consensus Rating | None |
|---|
Earnings (CINGW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, June 10, 2026 at 15:30 UTC.
Financials & Fundamentals (CINGW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -225.11% |
| Debt / Equity | 39.38 |
| Current Ratio | 2.55 |
| Total Cash | $25.89M |
| Total Debt | $7.43M |
| Free Cash Flow | $-11.92M |
Source: Nexqual, June 10, 2026 at 15:30 UTC.
Financial Health Score (CINGW)
Nexqual rates Cingulate Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 15:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $26M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -225%, ROA -69.7% |
Ownership (CINGW)
| Float | 12.94M |
|---|
Source: Nexqual, June 10, 2026 at 15:30 UTC.
Leadership (CINGW)
Cingulate Inc. is led by Shane J. Schaffer Pharm.D. (age 50), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 15:30 UTC.
| Co-Founder, CEO & Director | Shane J. Schaffer Pharm.D. (age 50) |
|---|---|
| Executive VP, CFO & Secretary | Jennifer L. Callahan (age 54) |
| Vice President of Investor & Public Relations | Thomas Dalton |
Major Backers & Investors (CINGW)
Notable institutional backers of Cingulate Inc. include CAPTRUST Financial Advisors, Citadel, according to Nexqual as of June 10, 2026 at 15:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CAPTRUST Financial Advisors | 0.43% |
| Citadel | 0.32% |
Source: Nexqual, June 10, 2026 at 15:30 UTC.
From Cingulate Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Roberts served as the Chief Financial Officer for VirMedica, Inc., a company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management.
Partnerships
- Schaffer   On September 23, 2021, we entered into an employment agreement with Dr.
- Callahan   On January 25, 2024, we entered into an employment agreement with Ms.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CING | Cingulate Inc. | USD 4.74 | ▲ 4.64% |
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
| DRMAW | Dermata Therapeutics, Inc. Warrant | USD 0.01 | ▼ 19.67% |
| DRTSW | Alpha Tau Medical Ltd. Warrant | USD 1.87 | ▲ 83.33% |
| NRSNW | NEUROSENSE THERAPEUTICS LTD C/W | USD 0.19 | ▼ 8.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:30 UTC. This page is informational and not investment advice.